Philip Morris International (NYSE: PM) shares ended a shortened trading week on a sour note, falling 0.67% on Friday to close at $177.38. The decline capped a weekly loss of 6.14%, pulling the stock well below its May 19 high of $193.05. The broader market held its ground, with the S&P 500 rising 0.2% to 7,580.06 and the Dow Jones Industrial Average climbing 0.7% to 51,032.46, according to Associated Press data. The New York Stock Exchange was closed Saturday and Monday for Memorial Day.
CEO Webcast in Focus
Next week, all eyes turn to Philip Morris CEO Jacek Olczak, who is scheduled to speak at Deutsche Bank's dbAccess Global Consumer Conference on Tuesday, June 2, at 11:15 a.m. CEST (5:15 a.m. ET). Investors expect Olczak to provide detailed updates on the company's smoke-free product portfolio, particularly Zyn nicotine pouches and IQOS heated-tobacco devices. Smoke-free products accounted for 43% of the company's first-quarter net revenue, underscoring their growing importance.
Regulatory Tailwinds and Analyst Views
Regulatory developments are also in the spotlight. Reuters reported that the U.S. Food and Drug Administration has begun using "enforcement discretion," choosing not to apply certain rules while reviewing applications. This could pave the way for more nicotine products to reach store shelves. Barclays analyst Pallav Mittal said this policy might "catalyse sales," estimating that Philip Morris could sell up to 12 million additional Zyn pouches this year if a new version launches.
However, the question remains whether Zyn can sustain growth without resorting to price cuts. Philip Morris lowered its full-year adjusted EPS guidance in April to $8.36-$8.51, citing regulatory challenges and competition. Jefferies analyst Andrei Andon-Ionita noted that Zyn volumes remain weak, and the "continued momentum loss" could benefit British American Tobacco's Velo brand.
Earnings and Brand Recognition
The company reported first-quarter adjusted diluted EPS of $1.96, a 16% increase, on net revenue of $10.15 billion. Olczak said results "exceeded our expectations," driven by IQOS. IQOS also earned a spot on Kantar's BrandZ 2026 top 100 list at No. 74, with Oggie Kapetanovic, president of heat-not-burn products, calling it a "powerful validation." IQOS now has over 35 million users worldwide.
Broader Tobacco Sector Weakness
Other tobacco stocks also declined. Altria Group fell 3.32% to $69.58, and British American Tobacco's U.S. shares slipped 1.80% to $61.79. This suggests the weakness extended beyond Philip Morris, though Zyn and IQOS remain key concerns for the stock.
Risks and Outlook
Former FDA tobacco chief Mitch Zeller warned that the new policy could lead to untested products reaching smokers, potentially posing risks or proving ineffective for quitting. If regulators backtrack, if youth usage concerns rise, or if competitors like Velo push prices lower, the Zyn growth story could falter.
Jefferies raised its price target for Philip Morris to $180 from $175 on May 27 but kept a Hold rating. The stock closed Friday just below that target. Olczak's webcast on Tuesday will need to deliver more than general comments on smoke-free growth to reassure investors.
Philip Morris is scheduled to report second-quarter results on Wednesday, July 22, at 9:00 a.m. EDT. Until then, the stock's direction will likely be shaped by the CEO's conference appearance, regulatory headlines, and any signs of buyer interest after the recent dip.
